ASPREE to evaluate effects of aspirin in elderly
This article was originally published in The Tan Sheet
Executive Summary
The Health Partners Research Foundation will enroll 19,000 healthy adults aged 70 years and older in the Aspirin in Reducing Events in the Elderly - a study to evaluate whether the potential benefits of low-dose aspirin outweigh the side effects for elderly people. Specifically, ASPREE will weigh the potential of aspirin to prolong healthy lifespan against the risk of bleeding - a well known side-effect of the drug. Researchers will evaluate participants for five years, according to study materials. The study also will evaluate the role aspirin could play in preventing heart disease. Many practitioners prescribe aspirin to help prevent secondary heart attacks and stroke, but this practice came under fire recently, John McNeil, head of the Monash School of Public Health and Preventative Medicine in Australia and a principal investigator for ASPREE, said in a July 6 release
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.